All In Biotech

Investigational drug · Phase 2

CPT-11

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastrointestinal Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

347

Any phase or sponsor naming "CPT-11"

First trial start

2025

Mar 25, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CPT-11", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Gastrointestinal Cancer

Approved drugs for the same conditions: Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "CPT-11" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2,871 on PubMed

Also in development for Gastrointestinal Cancer

  • OH2Phase 36 trials

    Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer

  • RMC-9805Phase 23 trials

    Revolution Medicines, Inc. · PDAC, Colorectal Cancer, CRC

  • DB-1324Phase 21 trial

    DualityBio Inc. · Gastrointestinal Cancer

  • DR30206Phase 21 trial

    Zhejiang Doer Biologics Co., Ltd. · Gastrointestinal Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.